Browse the evidence

Dapagliflozin (SGLT2 inhibitor) provides glycemic control equivalent to glipizide (sulfonylurea) while inducing significant weight loss and reducing hypoglycemia risk in type 2 diabetes patients inadequately controlled on metformin.

If you are taking metformin and your blood sugar is not controlled, adding Dapagliflozin can help lower your HbA1c just as effectively as Glipizide, but without the typical side effects of weight gain and low blood sugar. It works by removing excess sugar through urine. Be aware of a slightly higher risk of genital infections, which are usually treatable.

Testosterone replacement therapy increases fat-free mass, muscle size, and strength in hypogonadal men, even without resistance exercise training.

If you are a hypogonadal man, testosterone replacement therapy can significantly increase your muscle mass and strength, even if you do not engage in resistance exercise. The study used a standard replacement dose of 100 mg of testosterone enanthate weekly for 10 weeks. This resulted in an average increase of nearly 5 kg of fat-free mass and significant increases in muscle cross-sectional area. Ensure your testosterone levels are monitored by a healthcare provider.

Selenium-dependent selenoproteins (specifically deiodinases and glutathione peroxidases) are essential for thyroid hormone activation/inactivation and protecting thyroid cells from oxidative damage during hormone synthesis.

Support thyroid health with both iodine and selenium. Selenium is required for the enzymes that activate thyroid hormones and protect the thyroid gland from damage during hormone production.

Restoring Insulin-like Growth Factor 1 (IGF-I) levels or blocking Myostatin (Mstn) production can prevent or reverse glucocorticoid-induced muscle atrophy.

Current research suggests that therapies targeting IGF-I or Myostatin could protect muscle during steroid treatment. However, these are not yet standard clinical practices for all patients. Focus on maintaining protein intake and resistance training as foundational strategies while consulting your doctor about the specific risks and benefits of your steroid regimen.

Abdominal (visceral) obesity is an independent risk factor for coronary artery disease, hypertension, stroke, and type 2 diabetes, driven by a specific dyslipidemia phenotype characterized by hypertriglyceridemia, reduced HDL, and increased small, dense LDL particles.

If you have excess belly fat, your cardiovascular risk is significantly elevated regardless of your total cholesterol number. This is because your body produces more small, dense LDL particles and has lower HDL. To assess your true risk, ask your doctor for an Apo B test or an LDL particle size test, rather than relying solely on standard LDL cholesterol.

Insulin resistance in skeletal muscle and adipose tissue, characterized by impaired GLUT4 translocation, is a primary driver of whole-body hyperglycemia and type 2 diabetes.

Maintaining insulin sensitivity through regular physical activity (which stimulates GLUT4 translocation independently of insulin) and managing body fat levels are critical for preventing the transition from insulin resistance to type 2 diabetes.

Skeletal muscle is responsible for over 80% of postprandial glucose uptake, making it the primary driver of whole-body insulin resistance and glucose homeostasis.

Your skeletal muscle is the main engine for processing sugar from your food. When muscle function declines (due to aging or inactivity), your body struggles to manage blood sugar, leading to insulin resistance. Prioritizing muscle maintenance through activity is a fundamental strategy for metabolic health.

Exercise and insulin stimulate glucose uptake via distinct, independent signaling pathways that both converge on GLUT4 translocation.

Exercise improves blood sugar control through mechanisms that are separate from insulin. This means exercise can be beneficial even for those with severe insulin resistance, as it bypasses some of the defective insulin signaling pathways.

Excess weight (overweight or obesity) and lack of sufficient physical activity are associated with increased incidence of several cancers, including adenocarcinoma of the esophagus, colon and rectum, kidney, pancreas, postmenopausal female breast, and endometrial cancer.

Maintain a healthy weight and engage in at least 150 minutes of moderate-intensity aerobic activity per week. This is not just about appearance; it is a primary defense against several types of cancer, including breast, colon, kidney, and pancreatic cancers. The risk increases significantly with higher BMI and lower activity levels.

Biological adaptations to energy-restricted weight loss—including reduced leptin/insulin, increased hypothalamic NPY/AgRP, and suppressed energy expenditure—create a persistent drive for weight regain that actively counteracts behavioral efforts to maintain weight loss.

If you have lost weight, expect your body to fight back. Your hormones (leptin, insulin) and brain signals (hunger peptides) will change to promote weight regain. This is not a failure of willpower but a biological defense mechanism. Long-term success requires strategies that are 'comprehensive, persistent, and redundant' to counter these specific biological adaptations, rather than relying on willpower alone.

Metformin is marginally cost-saving compared to placebo over 10 years in high-risk adults, with slightly lower costs and nearly the same QALYs as placebo.

For high-risk individuals, metformin is a cost-saving option compared to no intervention, with slightly lower total medical costs and similar quality-adjusted life years over 10 years.

PPARγ agonists (glitazones) improve insulin sensitivity and lower glucose in type 2 diabetes by promoting fatty acid flux into adipose tissue, thereby reducing lipid interference with glucose utilization in muscle and liver.

Glitazones (like rosiglitazone and pioglitazone) treat type 2 diabetes by activating the PPARγ receptor. This shifts fatty acids into fat cells, allowing muscles and the liver to use glucose more effectively. They are insulin sensitizers, not insulin secretagogues.

Genetically predicted higher circulating levels of branched-chain amino acids (isoleucine, leucine, and valine) causally increase the risk of developing type 2 diabetes.

This research suggests that for individuals with specific genetic variants (like those affecting the PPM1K gene), the body's ability to break down branched-chain amino acids (found in protein) is impaired, leading to higher blood levels of these amino acids and a significantly increased risk of type 2 diabetes. It highlights that metabolic processing of protein varies by genetics. If you have a family history of diabetes, discussing your metabolic health with a doctor is important, but do not arbitrarily eliminate protein without professional guidance, as the root cause here is a specific enzymatic bottleneck, not protein itself for the general population.

Pharmacological inhibition of DPP-4 improves glycemic control in Type 2 Diabetes by preventing the degradation of endogenous incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon.

DPP-4 inhibitors (like vildagliptin, sitagliptin) are oral medications that help your body manage blood sugar more effectively by keeping your natural 'incretin' hormones (GLP-1 and GIP) active longer. They are safe, well-tolerated, and do not typically cause low blood sugar on their own. They work best when your blood sugar is high, stimulating insulin only when needed.

Elevated levels of C-reactive protein (CRP) and Serum Amyloid A (SAA) serve as independent predictors of cardiovascular events and are directly linked to obesity-induced inflammation.

High CRP and SAA levels are warning signs of inflammation linked to excess body fat. Monitoring these markers can help assess cardiovascular risk, and reducing body fat can lower these levels.

Adult weight gain is associated with a statistically significant increased risk of postmenopausal breast, endometrial, and ovarian cancers, as well as colon and kidney cancers, with risk increasing by approximately 6-39% per 5 kg of weight gain.

Avoiding adult weight gain is a proven strategy to reduce the risk of several cancers, particularly in postmenopausal women and men. Focus on maintaining a stable weight from early adulthood onwards, as even modest gains (5 kg) are linked to higher risks for breast, endometrial, ovarian, colon, and kidney cancers. This is especially important for postmenopausal women not using hormone replacement therapy.

Among long-acting GLP-1 receptor agonists, once-weekly exenatide is associated with the lowest risk of vomiting compared to other agents in the class.

If you are considering a GLP-1 medication and are concerned about vomiting, once-weekly exenatide appears to have the lowest risk of this specific side effect compared to other long-acting options like taspoglutide or dulaglutide. However, all GLP-1s carry a risk of GI side effects, so discuss your tolerance with your doctor.

Long-acting GLP-1 receptor agonists (dulaglutide, liraglutide, once-weekly exenatide) are associated with greater weight loss compared to short-acting agents (EBID, lixisenatide) when directly compared, although differences among long-acting agents are not clinically meaningful.

If weight loss is a priority, long-acting GLP-1 medications (like Liraglutide or EBID) tend to produce greater weight loss than short-acting Lixisenatide. However, there are no clinically meaningful differences in weight loss between the long-acting agents themselves (Dulaglutide, Liraglutide, Once-weekly Exenatide).

Light is the primary circadian synchronizer in humans, capable of eliciting weak (Type 1) or strong (Type 0) resetting depending on stimulus strength and timing.

Treat light as your primary sleep regulator. Morning bright light and evening dim light are critical for setting your internal clock. Avoid bright light at night and seek bright light during the day to maintain a healthy circadian rhythm.

Blue light (short-wavelength) is the most effective at resetting the human circadian system and suppressing melatonin.

Prioritize blue light exposure during the day to boost alertness and set your circadian clock. Avoid blue light from screens and bright lights in the evening to protect melatonin production.

Automated insulin delivery (AID) systems significantly improve glycemic control in people with type 1 diabetes by increasing time in range and reducing hypoglycemia compared to other therapies.

If you have Type 1 Diabetes, an Automated Insulin Delivery (AID) system is a highly effective tool to improve your blood sugar control. It automatically adjusts your insulin based on real-time glucose readings, helping you spend more time in your target range and less time in dangerous low or high states. While it still requires you to count carbs and announce meals, the system handles the fine-tuning. Ensure you receive proper training and support from your healthcare provider to get the most benefit and address any access barriers.

Women with polycystic ovary syndrome (PCOS) exhibit an intrinsic reduction in insulin sensitivity of approximately 27% compared to controls, a deficit that persists independently of body mass index (BMI), age, or diagnostic criteria.

If you have PCOS, you likely have an intrinsic metabolic disadvantage regarding insulin sensitivity, regardless of your weight. This is not just about 'eating less' or 'exercising more' to fix a weight problem; it is a physiological trait of the syndrome. Management should focus on strategies that improve insulin sensitivity (like specific dietary patterns or medications) rather than assuming weight loss alone will normalize metabolic health.

Higher body mass index (BMI) exacerbates insulin resistance in women with PCOS more severely than in healthy controls, with a 10-unit increase in BMI associated with a 28% greater reduction in insulin sensitivity in PCOS compared to a 15% reduction in controls.

For women with PCOS, gaining weight has a more damaging effect on insulin sensitivity than it does for women without PCOS. This means weight management is critically important for PCOS patients, not just for appearance, but to mitigate the amplified metabolic risk. Maintaining a healthy weight is a key strategy to counteract the intrinsic insulin resistance.

Obesity and weight gain exacerbate insulin resistance in PCOS by selectively impairing the PI3-K pathway while leaving the MAP-K pathway intact, leading to compensatory hyperinsulinemia and hyperandrogenism.

Understanding that weight gain worsens the hormonal imbalance in PCOS through specific insulin pathway defects can help patients see why weight management is critical for symptom control, not just appearance.